Organization
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 abstracts
Abstract
Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.Org: Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China, Department of Oncology, Fujian Cancer Hospital, Fuzhou, China, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Lung & Gastrointestinal Oncology Department, Hunan Cancer Hospital, Changsha, China, Department of Internal Medicine-Oncology, Hubei Cancer Hospital, Wuhan, China,
Abstract
Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.Org: Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China, Department of Oncology, Jilin Cancer Hospital, Changchun, China, Linyi Cancer Hospital, Linyi, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China,